We previously reported that cryoablation of early-stage, low-risk (ER +, PR +, HER2 –) unifocal invasive ductal carcinoma is safe and as effective as surgical resection, and that ice-ball margins beyond the original tumor can be reported.6 The next year, the 3 years interim results from the ICE3 trial of breast cancer cryoablation were published, supporting our findings.7 The gene discussed is ERBB2; the disease is breast cancer.